申请人:Teijin Limited
公开号:US06362177B1
公开(公告)日:2002-03-26
A compound represented by the general formula (I), a pharmaceutically acceptable acid addition salt thereof or a pharmaceutically acceptable C1-C6 alkyl addition salt thereof, and their medical applications. These compounds inhibit the action of chemokines such as MIP-1&agr; and/or MCP-1 on target cells, and are useful as therapeutic and/or preventative drugs in diseases, such as atheroclerosis, rheumatoid arthritis, and the like where blood monocytes and lymphocytes infiltrate into tissues.
一种由通式(I)表示的化合物,其药学上可接受的酸盐或药学上可接受的C1-C6烷基盐,以及它们的医药应用。这些化合物抑制趋化因子如MIP-1α和/或MCP-1对靶细胞的作用,并可用作治疗和/或预防药物,用于动脉粥样硬化、类风湿性关节炎等疾病,其中血液单核细胞和淋巴细胞浸润到组织中。